



<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Docket No.</b> 22338-00602	<b>Application No.</b> 09/613,038
	<b>Applicant(s):</b> Antonio J. Grillo-Lopez et al.	<b>Examiner:</b> Ronald B. Schwadron
	<b>Filing Date:</b> July 10, 2000	<b>Group Art Unit:</b> 1644

### U.S. PATENT DOCUMENTS

Examiner Initial	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
B3	280	5,595,721	Jan. 21, 1997	Kaminsky	-	-	Sept. 16, 1993
	281	6,410,319	June 25, 2002	Raubitschek	-	-	Oct. 20, 1999
	282	20020041847	April 11, 2002	Goldenberg	-	-	Aug. 3, 2001
	283	20030133930	July 17, 2003	Goldenberg	-	-	Jan. 24, 2003
	284	20030219433	Nov. 27, 2003	Hansen	-	-	Feb. 14, 2003
	285	20040202658	Oct. 14, 2004	Benyunes	-	-	Apr. 6, 2004
	286	20050112130	May 26, 2005	Bhat	-	-	Nov. 5, 2004
	287	20050191300	Sept. 1, 2005	Goldenberg	-	-	Apr. 13, 2005
	288	20060024300	Feb. 2, 2006	Adams	-	-	July 26, 2005
	289	20060034835	Feb. 16, 2006	Adams	-	-	June 7, 2005
	290	20060051349	Mar. 9, 2006	Goldenberg	-	-	Sept. 12, 2005

### FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
B3	291	WO 93/02108	Feb. 4, 1993	WIPO	-	-		
	292	WO 00/23573	Apr. 27, 2000	WIPO	-	-		
	293	WO 04/056312	July 8, 2004	WIPO	-	-		
	294	WO 04/091657	Oct. 28, 2004	WIPO	-	-		

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

B3	295	J Elliott et al., "Semi-Specific Immuno-Absorption and monoclonal Antibody Therapy in ANCA Positive Vasculitis: Experience in Four Cases," <i>Autoimmunity</i> 28(3):163-71 (1998).
	296	M Kobayashi et al., "Immunohistochemical Analysis of Arterial Wall Cellular Infiltration in Buerger's Disease (Endoarteritis Obliterans)," <i>J. Vascular Surgery</i> 29(3):451-8 (March 1999).
	297	M Schoeffel et al., "Elevated Expression of HLA-Class II Antigen Positive Peripheral Blood T Lymphocytes in Multiple Sclerosis Results of an 18 Month Longitudinal Study," <i>Zeitschrift Fuer Klinische Medizin (Berlin)</i> 46(12):918-21 (1991).
	298	Y Goto et al., "Increased Production of B Cell Growth Factor (BCFG) in Sjorgen's Syndrome," <i>J. Autoimmunity</i> 9(4):545-50 (1996).
	299	M Falcone et al., "B Lymphocytes Are Crucial Antigen-Presenting Cells in the Pathogenic Autoimmune Response to GAD65 Antigen in Nonobese Diabetic Mice," <i>J. Immunol.</i> 161(3):1163-8 (Aug. 1, 1998)


<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 8/3/06
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449) <span style="float: right;">SHEET 1 OF 2</span>	



INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-00602	Application No. 09/613,038
	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Ronald B. Schwadron
	Filing Date: July 10, 2000	Group Art Unit: 1644

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

335	300	L Chatenoud et al., "Anti-CD3 Antibody induces Long-Term Remission of Overt Autoimmunity in Nonobese Diabetic Mice," <i>Proc. Natl. Acad. Sci. (USA)</i> 91(1):123-7 (Jan. 4, 1994).
	301	Edwards, "Is Rheumatoid Factor Relevant?", <i>Challenges in Rheumatoid Arthritis</i> , Chapt. I, pp. 1-24 (HA Brid, ML Snaith eds. January 3, 1999).
	302	D Wendling et al., "A Randomized Double Blind, Placebo Controlled Multicenter Trial of Murine Anti-CD4 Monoclonal Antibody Therapy in Rheumatoid Arthritis," <i>J. Rheumatology</i> 25(8):1457-61 (Aug. 1998).
	303	EM Ruderman et al., "Oral glucocorticoids have no impact on the efficacy or safety profile of rituximab in rheumatoid arthritis (RA) patients with inadequate response to TNF inhibitors (REFLEX study)," forthcoming abstract publication.
	304	DG Maloney et al., "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma," <i>Blood</i> 84:2457-66 (1994).
	305	MJ Polyak & JP Deans, "Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure," <i>Blood</i> 99(9):3256-62 (2002).
	306	HB Lowman, "Differential Activities in a Series of Humanized Anti-CD20 Antibodies," presented at IBC Antibody Engineering Conference, San Diego, CA, December 2, 2003.

EXAMINER 	DATE CONSIDERED 8/3/06
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449) SHEET 2 OF 2	